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Abstract: OBJECTIVES Epinephrine is frequently used as an inotropic and vasopressor agent in critically
ill patients requiring hemodynamic support. Data from observational trials suggested that epinephrine
use is associated with a worse outcome as compared with other adrenergic and nonadrenergic vasoactive
drugs. We performed a systematic review and meta-analysis of randomized controlled trials to investigate
the effect of epinephrine administration on outcome of critically ill patients. DATA SOURCES PubMed,
EMBASE, and Cochrane central register were searched by two independent investigators up to March
2019. STUDY SELECTION Inclusion criteria were: administration of epinephrine as IV continuous infu-
sion, patients admitted to an ICU or undergoing major surgery, and randomized controlled trials. Studies
on epinephrine administration as bolus (e.g., during cardiopulmonary resuscitation), were excluded. The
primary outcome was mortality at the longest follow-up available. DATA EXTRACTION Two indepen-
dent investigators examined and extracted data from eligible trials. DATA SYNTHESIS A total of 5,249
studies were assessed, with a total of 12 studies (1,227 patients) finally included in the meta-analysis. The
majority of the trials were performed in the setting of septic shock, and the most frequent comparator
was a combination of norepinephrine plus dobutamine. We found no difference in all-cause mortality
at the longest follow-up available (197/579 [34.0%] in the epinephrine group vs 219/648 [33.8%] in the
control group; risk ratio = 0.95; 95% CI, 0.82-1.10; p = 0.49; I = 0%). No differences in the need for renal
replacement therapy, occurrence rate of myocardial ischemia, occurrence rate of arrhythmias, and length
of ICU stay were observed. CONCLUSIONS Current randomized evidence showed that continuous IV
administration of epinephrine as inotropic/vasopressor agent is not associated with a worse outcome in
critically ill patients.
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Objectives: Epinephrine is frequently used as an inotropic and 
vasopressor agent in critically ill patients requiring hemodynamic 
support. Data from observational trials suggested that epineph-
rine use is associated with a worse outcome as compared with 
other adrenergic and nonadrenergic vasoactive drugs. We per-
formed a systematic review and meta-analysis of randomized con-
trolled trials to investigate the effect of epinephrine administration 
on outcome of critically ill patients.
Data Sources: PubMed, EMBASE, and Cochrane central register 
were searched by two independent investigators up to March 
2019.
Study Selection: Inclusion criteria were: administration of epi-
nephrine as IV continuous infusion, patients admitted to an ICU or 
undergoing major surgery, and randomized controlled trials. Stud-
ies on epinephrine administration as bolus (e.g., during cardiopul-
monary resuscitation), were excluded. The primary outcome was 
mortality at the longest follow-up available.
Data Extraction: Two independent investigators examined and 
extracted data from eligible trials.
Data Synthesis: A total of 5,249 studies were assessed, with a 
total of 12 studies (1,227 patients) finally included in the meta-
analysis. The majority of the trials were performed in the setting 
of septic shock, and the most frequent comparator was a com-
bination of norepinephrine plus dobutamine. We found no dif-
ference in all-cause mortality at the longest follow-up available 
(197/579 [34.0%] in the epinephrine group vs 219/648 [33.8%] 
in the control group; risk ratio = 0.95; 95% CI, 0.82–1.10; p = 
0.49; I2 = 0%). No differences in the need for renal replacement 
therapy, occurrence rate of myocardial ischemia, occurrence rate 
of arrhythmias, and length of ICU stay were observed.
Conclusions: Current randomized evidence showed that contin-
uous IV administration of epinephrine as inotropic/vasopressor 
agent is not associated with a worse outcome in critically ill 
patients. (Crit Care Med 2019; XX:00–00)
Key Words: catecholamines; hemodynamic management; 
inotropes; intensive care unit; shock; vasopressors
A
dministration of inotropes and vasopressors is fre-
quently required in critically ill patients to restore 
and maintain adequate tissue perfusion (1). Among 
the different drugs available, catecholamines remain the most 
commonly used. However, the choice of the optimal mole-
cule in the different clinical settings remain controversial, and 
available data are insufficient to provide clear recommenda-
tions (2–8).
Epinephrine (or adrenaline) is a catecholamine with high 
affinity for both alpha and beta-adrenergic receptors (9). 
Epinephrine is a frequently used vasopressor and inotropic 
agent in a wide range of clinical settings, especially in patients 
with severe cardiogenic shock or postcardiac surgery myocar-
dial stunning (10). However, several studies suggest that admin-
istration of epinephrine is associated with several side effects, 
including increase in lactate levels (11), and even a worse out-
come in cardiogenic shock patients (12, 13). Nevertheless, a 
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clear detrimental effect on survival was never demonstrated in 
randomized controlled trials (RCTs) (11, 14).
The aim of the present systematic review and meta-analysis 
was to investigate the effect on survival of continuous epi-
nephrine infusion versus any control treatment in critically ill 
patients.
MATERIALS AND METHODS
The present systematic review and meta-analysis of RCTs was 
performed in accordance with Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guidelines and follow-
ing Cochrane Collaboration recommendations (15–18).
Search Strategy and Study Selection
RCTs comparing continuous epinephrine infusion versus 
treatment with any different kind of vasopressor and inotropic 
agents were included in this study. No exclusion by language 
or publication date was enforced. The PICOS criteria were fol-
lowed: Population (patients admitted to an ICU or undergoing 
major surgery); Interventions (administration of continuous 
IV epinephrine infusion); Comparison intervention (other 
inotropes/vasopressors, placebo, or standard treatment); Out-
come (survival); and Study design (RCTs).
In details, inclusion criteria were: administration of epi-
nephrine as IV continuous infusion, critically ill patients (de-
fined as patients admitted to an ICU or undergoing major 
surgery), and RCTs. Exclusion criteria were: epinephrine ad-
ministration as boluses (e.g., during cardiopulmonary resus-
citation), non-IV administration of epinephrine, neonatal 
studies, nonhuman studies, lack of data for outcome of interest, 
studies published as abstract only, and overlapping population.
We searched PubMed, EMBASE, and Cochrane central reg-
ister of controlled trials databases from inception up to March 
31, 2019. Backward snowballing was applied to retrieve ad-
ditional manuscripts. Eligibility assessment was performed 
independently by two investigators at title/abstract level and 
the final selection of included articles was based on complete 
manuscripts with disagreements solved by consensus.
Data Extraction
Two authors independently collected details on baseline char-
acteristics, periprocedural, and outcome data. These were 
verified by a third author. We extracted data following the 
intention-to-treat principle whenever possible. To gather ad-
ditional data, we contacted corresponding authors via e-mail.
Outcomes
The primary outcome was mortality at the longest follow-up 
available. Secondary outcomes were 28-/30-day mortality, 
myocardial ischemia, need for renal replacement therapy, 
new-onset arrhythmias (any type), supraventricular arrhyth-
mias, ventricular arrhythmias, stroke, bowel ischemia, limb is-
chemia, length of ICU stay, serum lactate levels 24 hours after 
randomization (or at the available time-point closest to 24 hr 
after randomization), and heart rate 24 hours after random-
ization (or at the available time-point closest to 24 hr after 
randomization). Outcomes were defined according to indi-
vidual studies Author’s definition.
Statistical Analysis
We calculated individual and pooled risk ratio (RR) for di-
chotomous outcomes with 95% CIs. For continuous variables, 
mean difference (MD) with corresponding 95% CI were cal-
culated. Continuous variables reported as median and inter-
quartile range or range were converted into mean and SD (19).
Heterogeneity analysis was performed with Cochran Q sta-
tistic and quantified with I2. Heterogeneity with an I2 greater 
than 25% was considered significant: fixed-effect and random-
effects models were used in case of low and high statistical 
heterogeneity.
Publication bias small study effect for primary endpoint 
was assessed with visual assessment of funnel plot (20). For 
pooled outcome analyses, a p value of less than or equal to 0.05 
was considered significant.
Risk of bias was assessed following the recommended seven 
items-tool of Cochrane Collaboration (randomized sequence 
generation, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessors, incomplete out-
come data, selective reporting, other bias) (21). Each item was 
evaluated by two trained investigators and an overall judgment 
of low, high, or unclear risk of bias provided. Studies were clas-
sified as “high risk of bias” if they had at least one item re-
ported as high risk of bias, at “unclear risk of bias” if they had 
at least one item judged to carry an unclear risk of bias, and at 
low risk of bias if all of the item were at low risk of bias.
In addition to the primary analysis including all included 
trials, we performed the following subgroup analyses: adult 
versus pediatric trials, septic versus nonseptic patients, and dif-
ferent control treatment.
The following sensitivity analyses were performed as fol-
lows: low risk of bias trials only; sequential removal of each 
individual trial; change of analysis methods; and change of 
summary statistics.
We used RevMan 5.3. software (Review Manager, The 
Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark).
RESULTS
A total of 5,249 references were examined at a title/abstract 
level. After initial screening, a total of 45 studies were retrieved 
as complete articles. After exclusion of further 33 trials that did 
not met inclusion criteria, a total of 12 studies randomizing 
1,227 patients were included in the analysis (Fig. 1) (10, 11, 14, 
22–30). Details of major exclusions and reason for exclusion 
are provided in the Supplementary Appendix (Supplemental 
Digital Content 1, http://links.lww.com/CCM/F177).
Trials’ Characteristics
Characteristics of included trials are reported in eTables 1 
and 2 (Supplemental Digital Content 1, http://links.lww.com/
CCM/F177). The majority of trials were performed in septic 
shock (seven trials, 644 patients) (11, 23–25, 27–29) followed 
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by cardiogenic shock (two trials, 87 patients) (10, 22), cardiac 
surgery (26), mixed ICU patients (14), and major noncardiac 
surgery (30) (one trial each) settings. Two trials were per-
formed in the pediatric setting (180 patients) (25, 29).
The most frequent control treatment was a combination 
of dobutamine plus norepinephrine (four trials, 412 patients) 
(11, 22, 23, 27), with one trials using placebo as control (30) 
and one trial using levosimendan (26). All other RCTs com-
pared epinephrine against another catecholamines.
Overall, risk of bias analysis showed that two included trials 
were at low risk of bias (11, 25) (accounting for 390 patients 
[31.8% of overall included patients]). A total of four trials were 
considered at high risk of bias (10, 22, 26, 28) (190 patients 
[15.5%]), and six at unclear risk of bias (Fig. 2) (14, 23, 24, 27, 
29, 30) (647 patients [52.7%]).
All-Cause Mortality
Overall, we found no difference in all-cause longest fol-
low-up mortality (197/579 [34.0%] in the epinephrine group 
vs 219/648 [33.8%] in the control group; RR = 0.95; 95% CI, 
0.82–1.10; p for effect = 0.49; I2 = 0%) (Fig. 3).
Sequential removal of each trial did not change magni-
tude and direction of treatment effect (lowest RR = 0.89; 95% 
CI, 0.73–1.09; p = 0.27; I2 = 0%; removing Annane et al (11) 
and highest RR = 0.99; 95% CI, 0.85–1.14; p = 0.87; I2 = 0%; 
removing Ventura et al [29]). Selecting only low risk of bias 
trials did not change magnitude and direction of the results 
(98/190 [51.6%] in the epinephrine group vs 103/200 [51.6%] 
in the control group; RR = 1.00; 95% CI, 0.83–1.21; p = 0.99; 
I2 = 0%, with two trials included). Changes of the summary 
statistics from RR to odds ratio or risk difference did not result 
in a change in significance of 
study findings. Similarly, for 
analysis with low heteroge-
neity, changing from fixed- to 
random-effects model did not 
alter significance of the results.
Visual inspection of funnel 
plot did not suggest presence 
of significant publication bias 




We found no statistically sig-
nificant differences in the 
occurrence rate of any of the 
secondary outcomes (Table 1; 
and eFigs. 2–13, Supplemental 
Digital Content 1, http://links.
lww.com/CCM/F177)
Subgroup Analyses
When studying adult versus 
pediatric studies (eTables 
3 and 4 and eFigs. 14–39, Supplemental Digital Content 1, 
http://links.lww.com/CCM/F177) we found significant sub-
group interaction on serum lactate levels, with lower lactate 
level in pediatric patients receiving epinephrine as compared 
with control group (MD for pediatric trials = –0.63 mmol/L; 
95% CI, –1.11 to 0.14; p = 0.01; I2 = 0%; p for interaction = 
0.02) (eTable 3 and eFig. 19, Supplemental Digital Content 1, 
http://links.lww.com/CCM/F177).
We also found a significant interaction between septic 
and nonseptic trials in serum lactate levels (p for interaction 
< 0.001), with high serum lactate levels in the epinephrine 
group in nonseptic trials (eTable 4 and eFigure 31, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F177).
DISCUSSION
We performed a systematic review ad meta-analysis of RCTs to 
investigate the effect of epinephrine administration on major 
clinical outcome of critically ill patients. We found that IV 
continuous administration of epinephrine as inotrope/vaso-
pressor in critically ill patients did not result in increased mor-
tality or differences in clinically relevant or safety outcomes. 
However, our systematic literature search highlighted that, de-
spite the widespread use of epinephrine, only 12 RCTs overall 
randomizing a total of 1,227 patients reported mortality data. 
Therefore, our results should be considered hypothesis-gener-
ating and underline the need for higher quality RCTs on epi-
nephrine use.
We found a possible subgroup interaction effect in serum 
lactate levels between trials performed in the setting of sepsis 
and other settings, with higher lactate level in the nonsep-
tic group. However, data from nonseptic trials derived from 
Figure 1. Flowchart for included trials. im = intramuscular, sc = subcutaneous.
Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Belletti et al
4 www.ccmjournal.org XXX 2019 • Volume XX • Number XXX
one small, single trial in patients with cardiogenic shock. 
Therefore, we believe these results should be interpreted with 
caution. Furthermore, we observed lower lactate level in pedi-
atric patients receiving epinephrine as compared with control 
group.
This is the first meta-analysis of RCTs investigating the role 
of epinephrine in critically ill patients outside the specific set-
ting of cardiopulmonary resuscitation. Our systematic liter-
ature search identified several trials comparing epinephrine 
with other vasopressors in critically ill patients. The largest 
trial performed so far compared epinephrine versus a com-
bination of norepinephrine and dobutamine in 330 patients 
with septic shock (11). In this multicenter RCT, no major dif-
ferences between the two groups were found, with the excep-
tion of a higher lactate levels in the epinephrine group which 
tended to disappear after 4 days. Another multicenter RCT by 
Myburgh et al (14) compared the effect of epinephrine and 
norepinephrine in 280 mixed ICU patients and confirmed 
no difference in mortality between epinephrine and norepi-
nephrine and an higher occurrence rate of lactic acidosis in the 
epinephrine group. In contrast to these findings, a recent ob-
servational trial suggested that epinephrine use might be asso-
ciated with higher mortality rates in patients with cardiogenic 
shock (12). This latter study was limited by the observational 
design, which does not allow to fully adjust for potential biases 
in treatment selection and baseline characteristics, as under-
lined by the AltShock group (31). In particular, the AltShock 
group underline that epinephrine is generally administered to 
the patients showing the most severe degree of hemodynamic 
compromise, frequently as a second-line agent. Therefore, it 
is not surprising that patients receiving epinephrine generally 
have a worse outcome than patients receiving other vasoactive 
agents such as norepinephrine or dobutamine (32).
Léopold et al (13) recently published a meta-analysis on 
the use of epinephrine in the specific setting of cardiogenic 
shock and found increased mortality associated with epineph-
rine use. Compared with the present work, the meta-analysis 
by Léopold et al (13) mainly included data from observational 
trials, with only one RCT specifically comparing epinephrine 
with another vasopressor included (10). Accordingly, we be-
lieve that findings from Léopold et al (13) provide interesting 
clues but are limited by intrinsic biases of observational trials. 
Finally, a Cochrane review investigating different vasoactive 
strategies for the treatment of cardiogenic shock/low cardiac 
output syndrome was able to identify only one RCT assessing 
epinephrine use, with a very low quality of evidence and no 
difference in mortality between epinephrine and control treat-
ment (33).
Our results suggest that, despite concerns raised by obser-
vational trials, use of low-dose epinephrine as an inotrope/
vasopressor in critically ill patients does not result in a worse 
outcome. Epinephrine is a potent catecholamine with a strong 
affinity for both β- and α-adrenergic receptors and provides 
positive inotropism, chronotropism, and vasoconstriction (9). 
Therefore, it is generally used when both an increase in car-
diac output and mean arterial pressure are required, the most 
typical setting being myocardial stunning following cardiac 
surgery and cardiogenic shock, while it is generally consid-
ered a second-line agent in septic shock. Results of our study 
confirm the general finding that the choice of the inotrope 
does not seem to have a major impact on clinical outcomes, 
providing that adequate hemodynamic parameters, oxygen 
delivery, and tissue perfusion are maintained. Accordingly, the 
use of epinephrine in ICU should not be discouraged, if both 
positive inotropism and vasoconstriction are required and the 
treating physician is more familiar with epinephrine than with 
other vasoactive agents or when a single agent if preferred. 
Current guidelines on management of cardiogenic and septic 
Figure 2. Risk of bias summary.
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shock recommend norepinephrine as first-line vasopressor, 
with epinephrine as rescue drug (2, 4, 6, 7). Our results should 
reassure intensivists and anesthesiologists that epinephrine is 
a safe alternative to norepinephrine. This might be particu-
larly important in low-resource settings, as the costs of epi-
nephrine are generally lower than other catecholamines. For 
Figure 3. Forest plot for all-cause mortality. df = degrees of freedom, M-H = Mantel-Haenszel.
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example, in Europe, a vial of epinephrine (0.5–1 mg) costs 
from less than 0.50 € to 0.85 € and a vial of norepinephrine 
(2 mg) is about 1.30 €.
On the other side, the epinephrine-induced increase in 
blood lactate should also be considered. The increase in lactate 
levels associated with epinephrine use is already documented 
and may be clinically relevant, given the well-recognized role 
of lactate as a marker of tissue perfusion in critically ill patients 
(2, 34–37). However, there is also general agreement that the 
epinephrine-induced increase in lactate is not associated with 
reduced tissue perfusion or harm, as also confirmed by our 
meta-analysis (38, 39). Nevertheless, it seems reasonable to 
use agents other than epinephrine in order to avoid potential 
confounders in monitoring lactate levels and hence adequacy 
of resuscitation. Of note, our analysis, in which we analyzed 
lactate levels at 24 hours from randomization, confirmed that 
increase in lactate associated with epinephrine use is generally 
transient. Interestingly, we found lower lactate level in pedi-
atric patients receiving epinephrine. This finding might be re-
lated to the fact that patients in the epinephrine group achieved 
hemodynamic stabilization earlier than the control group re-
ceiving dopamine in both trials. Accordingly, this might have 
translated in improved organ perfusion and lactate clearance, 
despite the effect of epinephrine on lactate production.
Our study also confirmed that epinephrine use is associ-
ated with a trend toward higher heart rate as compared with 
control treatments, which might explain the nonsignificant 
trend toward increased risk of myocardial ischemia. Therefore, 
our study suggests that epinephrine might be beneficial when 
increase in heart rate is desirable in order to increase cardiac 
output but should be used with caution in patients at risk for 
myocardial oxygen demand/supply mismatch.
We found a possible subgroup interaction effect in serum 
lactate levels between trials performed in the setting of sepsis 
and other settings, with higher lactate level in the nonseptic 
group. However, data from nonseptic trials derived from one 
small, single trial in patients with cardiogenic shock. Therefore, 
we believe these results should be interpreted with caution. 
Furthermore, we observed lower lactate level in septic pedi-
atric patients receiving epinephrine as compared with con-
trol group, which contributed to this heterogeneity. Of note, 
data from the largest trials performed in adults in this setting 
were not included in the lactate analysis, as data in the orig-
inal manuscripts (which clearly show higher lactate levels in 
the epinephrine group) were presented as figure only and no 
raw numbers were available for pooled analysis.
Our study has some limitations. We included RCTs performed 
in both adult and pediatric patients and in different clinical set-
tings. However, statistical heterogeneity was low in most of the 
analyses, and subgroup analyses did not suggest relevant inter-
actions with the exception of the lactate levels discussed above. 
Control treatment was too heterogeneous to perform adequate 
subgroup analyses; therefore, we cannot comment on specific 
comparisons between epinephrine and other vasoactive agents. 















Mean Difference  
(95% CI)
p for  
Significance I2
p for  
Hetero-
geneity
Longest follow-up mortality 12 197/579 219/648 0.95 (0.82–1.10) 0.49 0 0.51
28-/30-d mortality 8 150/468 154/488 1.01 (0.81–1.29) 0.87 26 0.22
Receipt of renal replacement 
therapy
4 60/264 65/285 1.01 (0.65–1.55) 0.98 34 0.21
Myocardial ischemia 6 17/362 14/427 1.53 (0.78–3.02) 0.21 0 0.91
ICU length of stay, d 3 220 230 –0.22 (–1.92 to 1.47) 0.80 0 0.98
Post-randomization lactate 
level, mmol/Lb
7 184 195 0.13 (–0.30 to 0.55) 0.55 71 0.002
Arrhythmias, overall 8 41/380 44/445 1.20 (0.81–1.77) 0.37 0 0.64
Supraventricular arrhythmias 3 21/191 22/199 1.00 (0.57–1.74) 0.99 20 0.26
Ventricular arrhythmias 5 16/266 12/322 1.47 (0.73–2.99) 0.28 0 0.48
Limb ischemia 4 8/277 10/293 0.83 (0.34–2.06) 0.69 7 0.34
Bowel ischemia 4 2/82 0/130 4.18 (0.47–37.27) 0.20 0 0.79
Stroke 4 4/228 3/284 1.61 (0.43–6.05) 0.48 0 0.64
Heart rate, beats/minb 8 204 218 4.81 (–2.00 to 11.62) 0.17 82 < 0.001
a Only total number is reported for continuous variables.
b At 24 hr from randomization, or value closest to 24 hr.
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The dose of epinephrine was also variable, and not amenable to 
pooled analysis, although most of the trials investigated doses in 
the range of 0.1–0.3 µg/kg/min, which is consistent with clinical 
practice. Finally, meta-analyses should be considered hypothe-
sis-generating rather than confirmative. Notably, while epineph-
rine is frequently used in everyday clinical practice in ICUs, we 
were able to identify only 12 RCTs (enrolling a total of 1,227 
patients) reporting mortality data. Therefore, adequately pow-
ered multicenter RCTs are required before definitive answers on 
epinephrine efficacy and safety can be provided.
CONCLUSIONS
Continuous infusion of epinephrine as inotrope/vasopressor 
is not associated with worse clinical outcomes in critically 
ill patients. A transient increase in serum lactate is com-
monly observed as compared with other vasoactive drugs in 
adult patients. A nonsignificant increase in heart rate, myo-
cardial ischemia, and ventricular arrhythmias has also been 
observed. Intensive care physicians should chose vasoactive 
agents according to the specific hemodynamic effects desired, 
their clinical experience with each specific agent, and available 
resources.
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